Skip to the main content.

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

MELBOURNE Australia, 5 June 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development, is pleased to announce that it has secured agreements critical to the development of its lead therapeutic program, AD-214. Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing services.

Read Full Press Release from AdAlta (PDF)

 

 

 

 

 

 

 

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization...

Read More
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...

Read More
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Durham, North Carolina (April 1, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing...

Read More